Navigation Links
Varian, Inc. Reports First Quarter 2008 Results
Date:1/23/2008

============ ============

NON-GAAP (ADJUSTED) FINANCIAL MEASURES (see also attached reconciliations of GAAP to Adjusted results for each of these measures):

(1) $127,661 on an adjusted basis excluding $1,391 in acquisition-related

intangible amortization, $480 in acquisition-related inventory write-

up amortization, $488 in restructuring and other related costs and

$109 in share-based compensation expense.

(2) $62,935 on an adjusted basis excluding $438 in acquisition-related

intangible amortization, $1,193 in restructuring and other related

costs and $1,414 in share-based compensation expense.

(3) $16,745 on an adjusted basis excluding $320 in restructuring and

other related costs and $115 in share-based compensation expense.

(4) $30,090 on an adjusted basis excluding the adjustments described in

items (1) - (3) above.

(5) $10,083 on an adjusted basis excluding the tax impact of the

adjustments described in items (1) - (3) above.

(6) $21,495 and $0.70 per diluted share, respectively, on an adjusted

basis excluding the adjustments (net of related tax effects)

described in items (1) - (3) above.

(7) $116,514 on an adjusted basis excluding $1,346 in acquisition-related

intangible amortization, $271 in acquisition-related inventory write-

up amortization and $108 in share-based compensation expense.

(8) $57,576 on an adjusted basis excluding $901 in acquisition-related

intangible amortization, $115 in restructuring and other related

costs and $2,609 in share-based compensation expense.

(9) $15,482 on an adjusted basis excluding $128 in share-based

compensation expense.

(10) $28,366 on an adjusted basis excluding the adjustments described in

items (7) - (9) above.

(11) $10,215 on an adjusted basis excluding
'/>"/>

SOURCE Varian, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy ... that it has signed a letter of intent ... has developed and patented a nanotechnology-based development platform ... products that enable rapid on-site collection and testing ... and health issues in an immediate, non-invasive and ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Fertility Associates ... Donor Egg Bank USA , a network of more ... Through this partnership, patients have fast access to a ... vitro fertilization, IVF . Fertility Associates of Memphis is ... this fertility treatment option. , Dr. William Kutteh ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Roche (SIX: ... of Bina Technologies, Inc. (Bina), a privately held ... , USA. Bina provides a big data ... generation sequencing (NGS) data. Bina,s proprietary on-market Genomic ... and academic researchers to perform fast and scalable ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... Boehringer Ingelheim today,announced that the company ... as the,world,s most respected biopharmaceutical employer. Science,s ... polls employees in the biotechnology,biopharmaceutical, pharmaceutical, and ... asked to rate companies based on 23 ...
... featured in oral presentation ... TSX Exchange Symbol: ... is pleased to announce that tomorrow it is making,an oral ... at the International Atherosclerosis Society (IAS),Workshop on HDL. The presentation ...
... New sol-gel inks developed by researchers at the University ... three-dimensional structures of metal oxides with nanoscale features. , ... nanoscale opens a new avenue to functional devices. Potential ... The researchers describe the new inks in a paper ...
Cached Biology Technology:Boehringer Ingelheim Receives Top Honor as World's Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 2Boehringer Ingelheim Receives Top Honor as World's Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 3Resverlogix is Presenting at IAS HDL Workshop 2Sol-gel inks produce complex shapes with nanoscale features 2
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Orleans, LA Research led by Wayne L. Backes, PhD, ... Health Sciences Center New Orleans School of Medicine, has found ... present in an individual, but also how they interact, and ... safely eliminated from the body or is converted into a ...
... Pa. , March 17 Orbel,s ... design your own PCB shield. Visit the BLS section ... from a wide variety of surface mount or ... The easy-to-use application lets you enter shield dimensions, ...
... A new study involving scientists from 13 different ... protection offers one of the most effective, practical, ... study, "Indigenous Lands, Protected Areas, and Slowing Climate ... a peer-reviewed scientific journal, and makes specific recommendations ...
Cached Biology News:LSUHSC research increases understanding of drug metabolism 2Orbel Introduces the Board Shielding Wizard 2Study highlights forest protected areas as a critical strategy for slowing climate change 2
... through 63 ligand binding ... a broad therapeutic range. ... many non human tissue ... assays. Used to ...
...
... Sequencer 20 System revolutionizes DNA sequencing, delivering ... The Genome Sequencer 20 System includes: ... and consumables for library construction, amplification, and ... de novo assembly The ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Biology Products: